ALPINE IMMUNE SCIENCES INC (ALPN)
US02083G1004 - Common Stock
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AIRC, ALPN, WIRE
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
Vertex is broadening its portfolio.
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now
These stocks could be near major inflection points.
3 Relatively Safe Growth Stocks You Can Buy and Hold
Low risk and high-reward potential? These stocks could offer both.
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
The biotech just added another potential growth driver to its pipeline.
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
The biotech just added another potential growth driver to its pipeline.
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Discover three biotech stocks with explosive growth potential. Don't miss out on these great picks this year.
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock
Vertex just laid claim to an asset that might be very valuable.
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock
Vertex just laid claim to an asset that might be very valuable.
Could This Stock Be the Next Biotech Buyout?
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears.
Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
Noteworthy Thursday Option Activity: CPRI, AMBC, ALPN
Which stocks are moving on Thursday?
Top movers analysis one hour before the close of the markets on 2024-04-11: top gainers and losers in today's session.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Let's take a look at the stocks that are in motion in today's session.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Thursday's session: gap up and gap down stocks
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.
Curious about the stocks that are showing activity before the opening bell on Thursday?
Thursday's pre-market session: top gainers and losers
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning!
Shareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with Vertex
/PRNewswire/ -- Ademi LLP is investigating Alpine (Nasdaq: ALPN) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
The companies expect the deal to close later this quarter.
Vertex to Buy Kidney Disease Drug Developer for $4.9 Billion
Vertex Pharmaceuticals Inc. agreed to buy Alpine Immune Sciences Inc. for a total equity value of about $4.9 billion, adding the biotech company’s immune treatments to its growing pipeline.
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
Alpine Immune Is Weighing Options After Takeover Interest
Alpine Immune Sciences Inc., a clinical-stage biotechnology company developing a treatment for inflammatory kidney diseases, is weighing options including a potential sale after attracting takeover interest, according to people with knowledge of the matter. The stock gained as much as 17%.